PT - JOURNAL ARTICLE AU - VARUN KUMAR AU - DANIEL RADIN AU - DONNA LEONARDI TI - Probing the Oncolytic and Chemosensitizing Effects of Dihydrotanshinone in an <em>In Vitro</em> Glioblastoma Model DP - 2017 Nov 01 TA - Anticancer Research PG - 6025--6030 VI - 37 IP - 11 4099 - http://ar.iiarjournals.org/content/37/11/6025.short 4100 - http://ar.iiarjournals.org/content/37/11/6025.full SO - Anticancer Res2017 Nov 01; 37 AB - Background: Temozolomide is the primary chemotherapeutic agent used to treat glioblastoma. However, many tumors are initially resistant to or develop resistance to temozolomide, mainly due to high levels of O6-methylguanine DNA transferase (MGMT) which repairs DNA damage traditionally caused by temozolomide. Dihydrotanshinone (DHT) is extracted from Salvia miltiorrhiza, a Chinese medicinal plant, and has also been shown to have antiproliferative effects on various cancer cell lines. DHT has been to shown to induce apoptosis via induction endoplasmic reticulum stress, that can reportedly sensitize cells to temozolomide. Materials and Methods: MTS cellular proliferation assays or trypan blue viability assays were used to determine the effects of DHT/temozolomide combinatorial treatment. Enzyme-linked immunosorbent assay (ELISA) was used to determine effects on MGMT and P-glycoprotein levels after singular and combinatorial treatment. Results: DHT had a synergistic oncolytic effect in a MGMT-deficient cell line and a sensitizing effect in a MGMT-expressing cell line. Cytotoxicity due to DHT was shown to be reactive oxygen species-dependent, while the combinatorial effect of DHT and temozolomide synergistically reduced MGMT and P-glycoprotein levels. Conclusion: DHT was shown to augment temozolomide efficacy, indicating that, since DHT can penetrate the blood–brain barrier, temozolomide in combination with DHT may represent a promising therapeutic option for glioblastoma.